DXY Forms Strategic Partnership with Johnson & Johnson Innovative Medicine China to Explore a New Digital Future for Healthcare
DXY and Johnson & Johnson Innovative Medicine China have signed a strategic partnership agreement.
HANGZHOU, China, August 14, 2026 -- DXY has signed a strategic partnership agreement with Johnson & Johnson Innovative Medicine China at DXY Center in Hangzhou. The two parties will work closely across key areas including academic collaboration, targeted physician engagement, patient management, and joint AI innovation. By drawing on their respective strengths in innovative medicines, digital capabilities, professional content ecosystems, and industry resources, they will jointly explore new models for innovation and growth in the pharmaceutical and healthcare industry, helping drive the industry's high-quality development.
Cherry Huang, President of Johnson & Johnson Innovative Medicine China, and Tiantian Li, Founder and Chairman of DXY, signed the agreement on behalf of their respective organizations. The strategic partnership brings the two organizations into a new phase of broader, deeper, and more forward-looking collaboration, opening a new chapter in digital innovation and collaborative value creation across the healthcare industry.
Joining Forces to Build a Digital Healthcare Ecosystem
Li Tiantian, Founder and Chairman of DXY, said:
"As a leading professional digital health platform in China, DXY has always been committed to connecting physicians, patients, and industry partners and advancing innovation in healthcare. This strategic partnership is an important step grounded in our shared values and long-term vision. Going forward, DXY will fully leverage its platform resources, content ecosystem, digital technologies, and AI innovation capabilities to work with its partners to explore more efficient, targeted, and higher-value solutions for the industry, thereby creating greater social value for physicians, patients, and the healthcare industry."
With more than 9 million registered healthcare professionals, DXY has broad reach and strong capabilities in engaging physicians and connecting healthcare professionals. The strategic partnership will explore innovative applications of digital tools in targeted physician engagement, patient education, and disease management, continuing to unlock the value of digital health services.
Joint AI innovation is one of the key directions of the strategic partnership. Against the backdrop of rapid global development of artificial intelligence, the parties will combine DXY's early leadership in integrating AI technologies with healthcare applications, including its self-developed AI tools for clinical decision support, with Johnson & Johnson Innovative Medicine China’s extensive expertise in pharmaceutical R&D and commercialization to explore innovative pathways for applying AI to advance the healthcare industry.
The signing of this strategic partnership agreement reflects the shared determination of DXY and Johnson & Johnson Innovative Medicine China to advance innovation in the healthcare industry.
Looking ahead, DXY will remain driven by innovation and focused on value creation. It will continue to explore new pathways for the healthcare industry in an era of digital and intelligent technologies, support the Healthy China initiative, and help drive the industry's high-quality development through continued innovation.